Evoclin is a U.S.-labeled prescription brand of clindamycin phosphate topical foam 1%, indicated in its prescribing information for acne vulgaris in patients 12 years and older. The Evoclin brand label identifies an aerosol foam that is distinct from skin gels, lotions and topical solutions. The dedicated clindamycin foam guide covers the broader foam category.
An Evoclin label associated with Mylan Pharmaceuticals is available in DailyMed and its archived NDC information identifies 50 g and 100 g can presentations. Those records establish the brand’s formulation and labeling history but are not a real-time claim that Evoclin is stocked nationally or by a specific pharmacy. Generic 1% clindamycin phosphate foam is also labeled in the United States; its availability and substitution status should be checked separately.
This Core brand guide explains the named foam, its single-ingredient formula, pressurized-container precautions, contraindications and appropriate prescription questions. It does not promise immediate access or suggest that a generic foam, gel or another acne medicine can be substituted without licensed pharmacist review.
Evoclin denotes clindamycin phosphate topical aerosol foam 1%, a skin-use antibiotic formulation. The U.S. label addresses acne in patients at least 12 years old; it is not an OTC cleanser and is not for oral, eye or vaginal use. The distinctive vehicle is a temperature-sensitive foam dispensed from a pressurized can.
The Mylan-branded record supplies a concrete product identity, while current stock and coverage remain pharmacy-specific questions. Use the table to separate label facts from the information a pharmacist must verify at the time of dispensing.
| Question | What can be stated | What is not established |
|---|---|---|
| Brand | Evoclin clindamycin phosphate foam 1% | Distinguish from generic foam and other brands |
| Labeled population | Acne vulgaris, age 12 and older | Needs individual clinician decision |
| Dosage form | Thermolabile aerosol foam | Not a tube of gel or bottle of solution |
| Historic package examples | 50 g and 100 g pressurized cans in Mylan NDC records | Listed package does not guarantee present stock |
| Safety | Flammable foam; formal GI-history contraindications | Read the exact current dispensed label |
| Access | Prescription and pharmacist verification | Not a no-Rx or guaranteed-delivery product |
DailyMed contains Evoclin prescribing information identifying Mylan Pharmaceuticals and the clindamycin phosphate foam 1% formulation. The labeling was revised in April 2018, and historical package records identify 50 g and 100 g aerosol cans. That documentation makes Evoclin a meaningful named brand entity to explain, independently of any individual pharmacy’s inventory.
A documented label, even one without an end date in a particular NDC listing, is not a live availability report. A pharmacist should confirm the current branded product and package if Evoclin is named on an existing prescription. The availability guide explains how to make that product-specific inquiry.
A clindamycin topical foam differs physically from a gel tube, emulsion lotion or alcohol-based solution. Different vehicles affect packaging, application experience and product selection, even when they all contain the same topical antibiotic ingredient.
The topical formulation hub compares the routes and forms; the gel guide addresses the separate gel market. This page intentionally does not duplicate those broader product guides.
The historical Evoclin product identity is clindamycin phosphate topical foam 1%. The term 1% does not prove equivalence to Cleocin T or other topical clindamycin products, nor does it mean that a foam may replace a fixed combination containing benzoyl peroxide.
A pharmacy should verify the complete composition and product record before considering a lawful alternative. If a historical note does not identify the full drug, concentration and route, it is insufficient for a dispensing decision.
If an older prescription or medical record mentions Evoclin, identify its original formulation and concentration before requesting a refill. A past drug label does not prove that the prescription is still legally refillable, medically appropriate or available in the same package today.
Ask the pharmacist whether the product record can be matched and whether a currently obtainable approved foam is an appropriate dispensing option. A recurrent acne flare may also warrant clinician reassessment rather than automatic renewal; see refill and renewal guidance.
Evoclin refers to an antibiotic-containing topical formulation. Similar-looking cosmetic foams or acne washes do not make a clindamycin product over the counter. Websites advertising a guaranteed antibiotic purchase without prescription checks are a warning sign.
Our clindamycin OTC-status guide explains the distinction and directs readers toward legitimate clinical evaluation where necessary.
A currently marketed generic clindamycin foam, if available through the pharmacy, would need a complete prescription and product-equivalence check. A gel or solution cannot simply be substituted because the active ingredient is clindamycin.
Ask the pharmacist what exact product can legally be dispensed and what prescriber authorization is needed. The generic-clindamycin guide provides the broader brand-versus-generic framework.
The suitability of topical clindamycin depends on acne presentation and the overall regimen. Dermatology guidelines generally recommend pairing topical antibiotics with benzoyl peroxide to limit antibiotic resistance. That recommendation does not authorize independent addition or switching of prescription medicine.
Read clindamycin for acne for the clinical context instead of treating a historical foam brand as a complete acne treatment plan.
Evoclin labeling specifically contraindicates the foam in individuals with a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis, including pseudomembranous colitis. These are formal labeled restrictions, not merely optional counseling points. Any suspected hypersensitivity or other serious prior antibiotic reaction should also be reported to the prescribing clinician.
Clindamycin can be absorbed after skin application, and significant or bloody diarrhea may signal severe colitis. The aerosol is flammable during and immediately after use and the can must be protected against heat, puncture and fire. Local burning, itching and dryness may occur. Contact a clinician promptly for significant diarrhea, a severe rash or a worsening reaction; see route-specific adverse effects for context.
A historical branded package description cannot supply a current cash price or insurance copay. Ask for a quote on the exact branded foam if it can be sourced, with package size and insurance rules confirmed. A proposed generic foam should receive a separate product and benefit check.
The topical cost guide explains cost differences among foam, gel and other vehicles. Avoid comparing an out-of-date brand price with a generic container of a different dosage form, or taking a merchant listing as proof of supply.
The relevant pharmacy questions are whether the prescription specifies Evoclin foam 1%, which manufacturer or labeler and can size can be supplied, and whether an approved alternative is permitted. Confirm the route, clindamycin concentration, quantity, labeling and patient-specific directions before accepting a different product.
If the named brand is not obtainable, the prescriber and pharmacist can evaluate a currently available clindamycin phosphate foam. A foam is not automatically exchangeable with a gel, lotion or antibiotic/benzoyl peroxide combination. The decision belongs to authorized professionals, not an online marketplace search.
For product specifications, start with the general clindamycin foam guide; for a valid U.S. prescription, consult prescription requirements. Neither page can guarantee any individual product is available.
If a pharmacy cannot identify the named brand, ask the prescriber to review alternative treatment or formulation options. Do not order a similarly named foam from an unverified international marketplace.
Evoclin is a U.S.-labeled prescription clindamycin phosphate 1% aerosol foam used for acne vulgaris in patients 12 years and older.
Yes. DailyMed contains prescribing information for the Evoclin-branded clindamycin phosphate foam, including a Mylan Pharmaceuticals record. A label does not prove a pharmacy has stock.
Inventory is pharmacy-specific and has not been established by this page. Ask a licensed dispensing pharmacy to confirm the exact branded can and quantity.
Evoclin is an aerosol foam in a pressurized container. A gel uses a different vehicle and packaging and is not automatically a permitted substitute.
Yes. Its label warns about fire, flame and smoking during and immediately after use. The pressurized container also has specific heat and handling precautions.
The label contraindicates the foam in individuals with a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis.
No. Topical clindamycin can be absorbed. Significant or persistent diarrhea needs prompt clinical attention and review of the medicine.
A licensed pharmacist must check the exact approved product, prescription, potential equivalence and applicable substitution rules; prescriber input may be needed.
Yes. It is a prescription clindamycin antibiotic, not an OTC acne foam or cleanser.